Infusion Reactions With Antibody Medicines: What to Expect
Most monoclonal antibody medicines can cause a reaction while they are being infused — fever, chills, flushing, itching or breathlessness, usually in the first hour or two of the very first dose. It is common, it is expected, and day-care units are built around it. Knowing what it looks like, and why the first dose is deliberately slow, takes most of the fear out of the first infusion day.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
What Are the Symptoms of a Monoclonal Antibody Infusion Reaction?
Fever, chills or shaking, flushing, itching, rash, headache, nausea and a feeling of tightness in the throat or chest are the usual symptoms. Breathlessness, wheeze, a fall in blood pressure and back or abdominal pain are the serious ones. Most reactions are mild to moderate and settle when the drip is slowed or paused.
An infusion reaction is the body responding to the antibody as it enters the bloodstream and finds its target for the first time. It is not a sign that anything has gone wrong, and it is not a sign that the wrong medicine was chosen. It is common enough that day-care units plan the whole first infusion around it.
This page applies across the whole antibody class rather than to one molecule. Rituximab, obinutuzumab, daratumumab, trastuzumab, cetuximab, brentuximab vedotin and polatuzumab vedotin all share the same basic pattern, differing mainly in how likely a reaction is and how long the first infusion runs. What follows is written once so that the individual molecule pages do not have to repeat it.
Commonly reported, and usually manageable
- Fever, chills and shaking — the single most recognisable pattern, often starting part-way through the first infusion.
- Flushing, itching, hives or a rash — usually on the face, neck and chest.
- Headache, nausea, tiredness or aching — a flu-like feeling that can last into the evening.
- A dry throat, a cough or a tickle in the throat — mild throat irritation is frequently reported.
Tell the nurse straight away
- Breathlessness, wheeze or chest tightness — the symptom that most often changes the management of an infusion.
- Throat swelling or difficulty swallowing — treated as urgent regardless of how mild it feels.
- Dizziness, faintness, palpitations or a sudden change in blood pressure.
- Severe back, flank or abdominal pain — uncommon, but it needs the infusion stopped.
- A widespread rash, swelling of the face or lips, or a sense that something is badly wrong.
Nothing on this list is an over-reaction to report. A reaction that is caught in its first minute is almost always managed by slowing the drip. The same reaction reported twenty minutes later is a harder problem.
When Do Infusion Reactions Usually Start?
Most of them start during the first infusion, in the first 30 to 120 minutes. A smaller number appear in the hours after the drip finishes. By the second or third cycle, reactions are far less common, which is why later infusions run faster and take less of the day.
| Typically starts | What can happen in this window | Where this matters most |
|---|---|---|
| First 30 to 120 minutes of the first infusion | The great majority of reactions. Fever, chills, rigors, flushing, itching, throat tightness, sometimes breathlessness or a change in blood pressure | Rituximab, obinutuzumab, daratumumab, trastuzumab. Reported at up to 77 per cent for any grade with the first rituximab infusion in its prescribing information |
| Within minutes of the very first exposure | A true allergic reaction, including anaphylaxis. Uncommon, but immediate and treated differently from an ordinary infusion reaction | Cetuximab above all, where pre-existing IgE antibodies against a sugar called alpha-gal can cause a severe first-exposure reaction |
| Up to about 4 hours after the infusion finishes | Most of the remaining reactions. This is what the observation period in the day-care unit is designed to cover | Daratumumab in particular, where nearly all reactions occur during the infusion or within 4 hours of completing it |
| Up to 24 to 48 hours afterwards | Delayed reactions. Uncommon, and usually breathlessness, wheeze, cough or nasal congestion rather than fever and chills | Reported up to 48 hours after a daratumumab infusion in its prescribing information |
| Second and later infusions | Much less common and usually milder. The rate is allowed to run faster precisely because the first infusion was tolerated | All antibody medicines. Reaction rates fall steeply after the first exposure |
| First cycles of a bispecific T-cell engager | Cytokine release syndrome, which is a different and potentially more serious event than an infusion reaction and needs inpatient monitoring | Blinatumomab, and cell therapies such as CAR-T. These are managed under a separate protocol, not as an ordinary day-care infusion |
Sources: the prescribing information for rituximab, obinutuzumab and daratumumab; published infusion-reaction series in haematology and oncology pharmacy literature; and the ESMO Open 2024 review of infusion-related reaction management in cancer therapy. Reviewed August 2026. Individual protocols differ between hospitals.
Did you know?
Most infusion reactions to antibody medicines are not allergies. They are caused by a burst of cytokines released as the antibody binds its target on a large number of cells at once — which is why they are worst on the first dose, when the target cell mass is at its largest, and much milder afterwards. It is the same biology that makes the treatment work, arriving faster than the body would like.
Why Does the First Dose Take So Much Longer?
Because the rate is deliberately started low and increased in steps only while your observations stay stable. Premedication is given first, the infusion begins slowly, the nurse checks vital signs at each step, and an observation period follows. A first antibody infusion of four to six hours is normal, not a delay.
Families frequently arrive expecting a short appointment and leave having spent the day in the unit. The length is designed in. Two things are being managed at once: the antibody meets the largest number of target cells it will ever meet on day one, and there is no way to know in advance how any individual will respond to it.
The rate escalation is the safety mechanism. Each step up is a small test. If observations stay stable, the rate rises again after 30 minutes. If they do not, the infusion pauses at a rate the body has already tolerated. This is why an infusion that runs slowly is a sign the protocol is working, not a sign that something has gone wrong.
| Medicine | First infusion | Later infusions |
|---|---|---|
| Rituximab | Started at 50 mg per hour, increased by 50 mg per hour every 30 minutes to a maximum of 400 mg per hour if no reaction occurs | Started at a higher rate and escalated in larger steps. A shorter schedule is used in selected patients who tolerated the first infusion |
| Obinutuzumab | The first 1,000 mg dose is split across two days: 100 mg on day 1 given at 25 mg per hour over four hours with no rate increase at all, then 900 mg on day 2 | Rate escalation is allowed once day 1 and day 2 have been tolerated |
| Daratumumab, intravenous | Premedication one to three hours beforehand, then a long infusion. Published series report a first infusion averaging around seven and a half hours | Substantially shorter, and a rapid schedule is used from later cycles in many protocols. The subcutaneous formulation is injected over minutes instead |
| Trastuzumab | Given over about 90 minutes, with an observation period afterwards | Often shortened once the first infusion has been tolerated |
| Cetuximab | Given slowly with an observation period afterwards, because a severe first-exposure reaction is a recognised risk with this molecule | Observation is usually shortened once the first infusion has been tolerated |
Rates and schedules above are drawn from the published prescribing information for each molecule and are given to explain why the day is long. They are not a dosing instruction. The rate used for any individual is set by the treating team and adjusted to what that person tolerates on the day.
Who These Medicines Are Not For
An antibody medicine is not for you if the target it is built to grab is not present on your cancer. A CD20-negative lymphoma rules out rituximab and obinutuzumab. A CD38-negative myeloma rules out daratumumab. A HER2-negative breast cancer rules out trastuzumab. A laboratory report, not a diagnosis name, decides this, and most patients with cancer in India will not be candidates for the newer antibody medicines at all.
These medicines are also not for anyone who has had a severe or anaphylactic reaction to that same molecule before. That is the one situation in which an antibody is discontinued permanently rather than restarted at a slower rate. Beyond that, active or uncontrolled infection, pregnancy and breastfeeding, poor performance status and severe organ impairment all change the risk picture. Anti-CD20 antibodies carry a recognised risk of hepatitis B reactivation, which is why hepatitis B screening before treatment is standard. Trastuzumab and pertuzumab need cardiac monitoring and are approached cautiously where heart function is already reduced. Bispecific T-cell engagers such as blinatumomab need a centre able to monitor and manage cytokine release syndrome, which is not an ordinary day-care capability.
And this page is not a dosing guide, not a substitute for the approved label or your own protocol, not a statement that CION stocks, supplies or dispenses any medicine named here, not a price for any molecule, and not a guide to paediatric, off-label or clinical-trial use. There is no route to any of these medicines outside a prescription, dispensed and infused under specialist supervision.
How Are Infusion Reactions Prevented?
With premedication, a slow starting rate and close observation. Paracetamol and an antihistamine are given 30 to 60 minutes before, a corticosteroid where the protocol calls for one, and the infusion is stepped up only while observations stay stable. Splitting the first obinutuzumab dose across two days is part of the same strategy.
- Premedication before the drip starts. Paracetamol and an antihistamine are standard. Daratumumab protocols give premedication one to three hours ahead, and a corticosteroid is added where the regimen requires it.
- A low starting rate with stepped escalation. Each increase is a small test of tolerance, held for 30 minutes before the next step.
- Observation and recorded vital signs. Blood pressure, pulse, temperature and oxygen saturation are checked at intervals during the infusion and after it finishes.
- Dose splitting where the risk is highest. The obinutuzumab first dose is divided across two days in its prescribing information for exactly this reason.
- Emergency medication kept at the chairside. Antihistamines, steroids, oxygen and adrenaline are available in the room before the infusion begins, not fetched afterwards.
What helps on the day
Eat and drink normally beforehand unless told otherwise, and take the premedication exactly as prescribed rather than skipping it because you feel well. Tell the team about any previous reaction to any infusion, any drug allergy, and any recent tick bite before a first cetuximab dose. Bring someone with you, plan for a long day, and report the first odd sensation rather than the third. Almost every reaction that stays mild is one that was reported early.
Is an Infusion Reaction the Same as an Allergy?
No. An infusion reaction is a cytokine response as the antibody meets its target, commonest on the first dose and usually managed by slowing the drip. A true allergy is IgE-driven, can strike within minutes of first exposure, and may stop the molecule permanently. Immune-related side effects are a third thing entirely.
The distinction matters because it decides whether treatment continues. Families often hear the word reaction and assume the medicine has been ruled out for good. In most cases it has not.
| Infusion-related reaction | True allergic reaction | Immune-related side effect | |
|---|---|---|---|
| When it happens | During the infusion, usually the first one, or within a few hours of it | Within minutes of exposure, sometimes the very first exposure | Weeks to months into treatment, and sometimes after it has finished |
| What is going on | Cytokines released as the antibody binds its target on many cells at once | IgE antibodies against the drug or a sugar attached to it, such as alpha-gal with cetuximab | The immune system attacking healthy tissue, most associated with checkpoint inhibitors |
| Typical symptoms | Fever, chills, rigors, flushing, itching, throat tightness, breathlessness | Hives, swelling of the face or throat, wheeze, collapse, a sudden fall in blood pressure | Diarrhoea, cough or breathlessness, rash, thyroid or liver changes, fatigue |
| What the team does | Slows or pauses the infusion, treats the symptoms, restarts at a reduced rate | Stops the infusion immediately and treats it as an emergency | Investigates the organ involved and treats separately, often with steroids |
| Can the medicine continue? | Usually yes, with stronger premedication and a slower rate | Often no for that molecule | Depends entirely on the organ affected and the severity |
Checkpoint inhibitors sit in the third column rather than the first. Infusion reactions to pembrolizumab, nivolumab, atezolizumab and durvalumab are uncommon; their characteristic problems are delayed immune-related effects that appear long after the infusion is over. That is one of the clearest differences between the older antibody medicines and the newer ones.
What Happens If a Reaction Starts During the Infusion?
The infusion is paused or slowed, symptoms are treated, and it is restarted at a reduced rate once things settle. That covers the large majority of reactions. Only a severe reaction, an anaphylactic reaction, or one that cannot be controlled leads to the molecule being stopped for good.
- The drip is paused or slowed. This alone resolves many mild reactions within minutes, because the reaction is driven by how fast the antibody is arriving.
- Symptoms are treated. An antihistamine, paracetamol, a steroid, oxygen or fluids are given depending on what is happening. Observations are recorded throughout.
- The infusion is restarted at a reduced rate. Commonly around half the rate that triggered the reaction, then escalated again more cautiously if it is tolerated.
- A severe reaction stops the infusion for the day. Anaphylaxis, or a reaction that returns despite treatment, means the molecule is not restarted, and in some cases is discontinued permanently.
- It is written into the record for next time. Premedication is strengthened, the starting rate is lowered, and the next cycle is planned around what happened at this one.
Does a reaction mean the treatment is not working?
No. This is one of the most common worries in the chair, and it has a clear answer. The severity of an infusion reaction is not a measure of how well the medicine is working, in either direction. A patient who reacts strongly is not being told the treatment has failed, and a patient who feels nothing at all is not being told it is doing nothing. Whether treatment is working is assessed on scans, blood tests and marrow or biopsy findings at the points your protocol specifies — never on how the first infusion felt.